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ABSTRACT 
Objective. To develop classification criteria for macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA).  
Methods. A multistep process, based on a combination of expert consensus and analysis of real patient data, was conducted. A panel of experts 
was first asked to classify 428 patient profiles as having or not having MAS, based on clinical and laboratory features at disease onset. The 428 
profiles comprised 161 patients with sJIA-associated MAS and 267 patients with a condition potentially confusable with MAS (active sJIA without 
evidence of MAS, or systemic infection). Next, the ability of candidate criteria to classify individual patients as MAS or non-MAS was assessed by 
evaluating the agreement between the classification yielded by the criteria and the consensus classification of the experts. The final criteria were 
selected in a consensus conference.  
Results. Experts achieved consensus on the classification of 391/428 (91.4%) patient profiles. A total of 982 candidate criteria were tested in silico. 
The 37 best performing criteria and 8 criteria obtained from the literature were evaluated in the consensus conference. During the conference, 
82% consensus among experts was reached on the final MAS classification criteria. In cross-validation analyses, these criteria had sensitivity 0.72-
0.73 and specificity 0.97-0.99. Agreement of the criteria with the original diagnosis by the treating physician was high (kappa = 0.72-0.76). 
Conclusion. We have developed a set of classification criteria for MAS complicating sJIA and provided preliminary evidence of their construct 
validity. Prospective validation is required to confirm the high accuracy of the criteria. 
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INTRODUCTION 
Macrophage activation syndrome (MAS) is the term used to describe a potentially life-threatening complication of systemic inflammatory 
disorders, which occurs most commonly in systemic juvenile idiopathic arthritis (sJIA) and in its adult equivalent, adult-onset Still’s disease
1-4
. MAS 
is characterized by an overwhelming inflammatory reaction due to an uncontrolled and dysfunctional immune response involving the continual 
activation and expansion of T lymphocytes and macrophages, which results in massive hypersecretion of pro-inflammatory cytokines5,6. 
The clinical picture of MAS is high, nonremitting fever, hepatosplenomegaly, generalized lymphadenopathy, central nervous system (CNS) 
dysfunction, and hemorrhagic manifestations. Typical laboratory abnormalities include pancytopenia, increased levels of ferritin, liver enzymes, 
lactate dehydrogenase, triglycerides, D-dimers, and soluble interleukin (IL)-2 receptor α (also known as soluble CD25, sCD25), and decreased 
fibrinogen levels. A characteristic histopathologic feature of MAS is the accumulation of well-differentiated macrophages exhibiting 
hemophagocytic activity in bone marrow biopsy specimens or aspirates7. Although the estimated prevalence of MAS in sJIA is around 10%, recent 
reports suggest that subclinical MAS may occur subclinically in as many as 30-40% of sJIA cases8,9.  
MAS can result in progressive multi-organ failure and eventually a fatal outcome. Recent studies indicate a mortality rate of 8%10,11, making 
timely diagnosis and prompt initiation of appropriate treatment imperative. However, early recognition of MAS is often challenging, given the lack 
of a single pathognomonic clinical or laboratory parameter. Furthermore, histopathologic hemophagocytosis may not be present in the initial 
stages12,13 and lacks specificity for hemophagocytic syndromes14. In addition, the features of MAS may be hard to distinguish from those 
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conditions that may present with overlapping manifestations, such as flares of sJIA or systemic infections. Recently, a wide disparity in the 
frequency and severity of the classical clinical and laboratory features across patients has been observed10,11. 
The difficulties in diagnosing sJIA-associated MAS emphasize the need for accurate criteria that aid physicians in identifying MAS in its earliest 
stages and in distinguishing it from other conditions. The recognition that the syndrome is clinically similar to HLH has led some to recommend 
use of the HLH-2004 diagnostic guidelines15. An alternative approach is based on the application of the preliminary diagnostic guidelines for MAS 
complicating sJIA
16
. However, although both guidelines have been utilized for detecting MAS in sJIA, each has several limitations
17
. Altogether, the 
diagnostic difficulties, the recent therapeutic progress5, and the advances in understanding MAS pathophysiology and underlying genetic defects5, 
18-20 highlight the need for well-established classification criteria.  
The primary purpose of the international collaborative project described herein was to develop a set of classification criteria for MAS 
complicating sJIA, based on a combination of expert consensus, available evidence from the medical literature, and analysis of real patient data.  
 
METHODS 
A multistep process strategy was used in developing the classification criteria and included the following phases: 1) Delphi survey among 
international pediatric rheumatologists aimed to identify MAS features potentially suitable for inclusion in classification criteria
21
); 2) large-scale 
data collection of patients with sJIA-associated MAS and two potentially confusable conditions; 3) web-based consensus procedures among 
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experts; 4) selection of candidate criteria through statistical analyses; 5) selection of final classification criteria in a consensus conference; 6) cross-
sectional validation of final classification criteria. 
Data collection of patients with MAS and confusable conditions. The design, inclusion criteria and data collection procedures of this part of 
the project have been described in detail previously10,11,17. Briefly, international pediatric rheumatologists and pediatric hemato-oncologists were 
invited to participate in a retrospective cohort study of patients with sJIA-associated MAS and with 2 conditions potentially confusable with MAS, 
represented by active sJIA not complicated by MAS and systemic infection.  
For patients with MAS, collected information included demographic, clinical, laboratory and histopathologic features at 3 time points: 1) last 
visit before onset of MAS; 2) onset of MAS; 3) full-blown MAS. Because the classification criteria were aimed to identify MAS in its earlier stages, 
only laboratory data recorded at onset were retained. Data for patients with confusable conditions were also obtained at disease presentation. 
Except for blood counts and acute phase reactants, values of laboratory parameters were tested using both the original values provided by each 
local laboratory and the values standardized according to the international standard (SI) unit system based on their normal ranges, as reported10. 
A total of 1,111 patients, 362 with sJIA-associated MAS, 404 with active sJIA without MAS, and 345 with systemic infection were reported by 
95 pediatric subspecialists practicing in 33 countries in five continents. The features of MAS and comparison patients have been described 
elsewhere
10,11,17
. 
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Web-based consensus procedures among experts. At present, there is no single pathognomonic  feature for MAS. Furthermore, no validated 
diagnostic criteria are available. In order to classify patients as having or not having MAS, we, therefore, decided to use expert consensus as the 
“gold standard”. Based on publication records and experience in the care of children with MAS and related disorders, a panel of experts was 
created, which was composed of 20 pediatric rheumatologists and 8 pediatric hemato-oncologists. 
The experts were asked to classify a total of 428 patient profiles as having or not having MAS, based on the clinical and laboratory features 
recorded at disease onset. The 428 profiles were selected randomly among the 1,111 collected patients and comprised 161 patients with MAS, 
140 patients with active sJIA without evidence of MAS, and 127 patients with systemic infection. A selection bias was unlikely, as the 
characteristics of selected and unselected patients were comparable (data not shown). The experts were purposely kept unaware of the original 
diagnosis as well as of the overall course of the patient. 
Each patient profile included information about the presence or absence of key clinical manifestations, and the value and normal range of 
laboratory parameters at the respective institutions. Based on these data, all experts were asked to classify each patient as MAS or non-MAS. The 
minimum level of agreement among experts was set at 80%. If an 80% consensus was not attained, the patient profile was discussed in a further 
round. Profiles for which consensus was not achieved at the final round were declared non interpretable and discarded from further analyses. 
Three rounds of voting were used, with comments and voting from participants available, to augment the number of consensus decisions. 
All web-based consensus procedures were conducted by the Pediatric Rheumatology International Trials Organization (PRINTO). 
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Selection of best classification criteria through statistical analyses. All statistical analyses aimed to select the best classification criteria were 
conducted only on the sample of patients who achieved experts’ consensus about the diagnosis of MAS or non-MAS. The cutoff values for 
laboratory tests were calculated through the receiver operator characteristic (ROC) curve method, by identifying the point on the ROC curve that 
discriminated best between patients classified as MAS or non-MAS by the experts. 
The aim of this exercise was to assess the ability of candidate criteria to classify individual patients as having or not having MAS, and to 
evaluate the agreement between the classification yielded by the criteria and the consensus classification of experts. Candidate classification 
criteria were partly derived from the literature and partly generated from the study data.  
Literature criteria included: a) the preliminary diagnostic guidelines for MAS complicating sJIA16; b) the same guidelines modified with the 
addition of the item ferritin at various threshold levels (500, 1,000 or 1,500 ng/ml); c) the HLH-2004 diagnostic guidelines
15
, adapted by 
eliminating 3 of the 8 items, because information about presence of hemophagocytosis was not available for both comparison groups, and neither 
NK-cell activity nor sCD25 levels were determined in all patients. Criteria obtained from the study data were generated in 2 ways: 1) Through the 
evaluation, by the steering committee of the project, of all combinations of clinical and laboratory variables (see some examples in the online 
supplementary Table T1) (combination of criteria approach). 2) By assigning a weight to clinical and laboratory variables, on the basis of their 
association with the diagnosis of MAS made by the experts, through multivariable logistic regression analyses. For each combination of variables 
that were significantly associated with the diagnosis of MAS in logistic regression models, the rule was to convert the odds ratio of each variable 
to its percentage value out of a total of 100. Each set of criteria was, then, composed by a group of variables whose sum of weights made up a 
Page 10 of 37
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
10 
 
total score of 100 (MAS score). The cutoff value in the MAS score that was associated with the higher likelihood of the presence of MAS was 
obtained by calculating the point on the ROC curve which corresponded to the highest sensitivity and specificity. 
A total of 982 candidate classification criteria were tested. For each set of criteria, we calculated the sensitivity (ability of the criteria to 
identify a patient as having MAS who had been classified as having MAS as per the expert panel), the specificity (ability of the criteria to identify a 
patient as not having MAS who had been classified as not having MAS by the experts), the positive and negative predictive value, the area under 
the ROC curve (AUC-ROC), and the kappa value for agreement between the classification yielded by the criteria and the classification made by the 
experts. Although there was one single model with the highest predictive value (criterion no. 929 in online supplementary Table T1), we 
generated multiple combinations for comparison because we believed that less predictive models could have more face validity with the experts. 
Nevertheless, it was established that in order to qualify for inclusion in expert voting procedures at the consensus conference, a set of 
classification criteria should demonstrate a kappa value ≥ 0.85, a sensitivity ≥ 0.80, a specificity ≥ 0.93, and an AUC-ROC ≥ 0.90. An exception was 
made for the historical literature criteria, which were retained for further consideration even if they did not meet all statistical requirements. 
 
Selection of the final classification criteria at consensus conference. The International Consensus Conference on MAS Classification Criteria 
was held in Genoa, Italy, on March 21-22, 2014. The meeting was attended by all 28 experts who participated in web-consensus evaluations and 
was facilitated by 2 moderators (NR, HB) with expertise in nominal group technique (NGT). The overall goal of the meeting was to decide upon a 
preliminary set of classification criteria, using a combination of statistical and consensus formation techniques. 
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A plenary session was first held to illustrate the scope, methodology, and flow of the project, the results of the Delphi survey, the 
characteristics of patients enrolled in the data-collection, the results of web-based consensus procedures and of statistical analyses of candidate 
classification criteria, and the methodology of the NGT. Participants were then randomized into two equally sized nominal groups and, using NGT, 
were asked to decide, independently of each other, upon which of the classification criteria were easiest to use and most credible (face/content 
validity), ranking the 5 best from 5 (highest face/content validity) to 1 (lowest). All experts were connected by their laptop to a central computer 
and submitted all their rankings electronically. A series of repeated independent voting sessions were held until the top 3 classification criteria 
were selected by each voting group. Then, an 80% consensus was attained on the best (final) set of classification criteria in a session with the two 
tables combined. 
 
Analysis of the association between the variables included in the final classification criteria and the web-based experts’ consensus 
evaluations. The association between the final classification criteria and the web-based evaluations made by the experts was assessed by multiple 
logistic regression, which used as explanatory variables the individual items included in the final classification criteria and as the dependent 
outcome the web-based experts’ consensus on patients’ classification as MAS or non-MAS. The effect was expressed in terms of odds ratios, and 
95% confidence intervals were calculated; statistical significance was tested by the likelihood ratio test. The AUC-ROC of the model was used as an 
indicator of its predictive ability. The purpose of this post-consensus analysis was to evaluate which were the variables that most influenced the 
experts’ decision to classify the patients as having or not having MAS. 
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Cross-sectional validation of final classification criteria. This analysis was performed by assessing the performance of the criteria, in terms of 
sensitivity, specificity, negative predictive value, positive predictive value, AUC-ROC, and kappa value, in discriminating patients with MAS from 
patients with the 2 confusable conditions (combined in a single group), using the original diagnosis made by the caring physician (i.e. the 
investigator who entered the patient’s data in the study website) as the gold standard. This analysis was made on both the entire sample (n = 
1,111) and the restricted sample (n = 683) of patients not used for expert evaluations. Only patients who had all items included in the final 
classification criteria available were used for the analyses. 
 
RESULTS 
Results of web-based consensus procedures among experts. After three rounds of web-evaluations, the experts achieved consensus on the 
classification of 391 (91.4%) of the 428 patient profiles examined (Figure 1). A total of 95 patients were classified as MAS by the experts, 88 of 
whom had been diagnosed as MAS also by the treating physician; in 3 and 4 patients the original diagnosis had been sJIA without MAS and 
systemic infection, respectively. A total of 296 patients were classified as non-MAS by the experts, 47 of whom had been diagnosed as MAS by the 
treating physician. Thirty-seven patient profiles for which an 80% of consensus among experts was not reached were discarded. The comparison 
of clinical and laboratory features of patients diagnosed as MAS or non-MAS by the experts is shown in Table 1. Overall, patients who had the 
diagnosis of MAS confirmed by the experts had more severe clinical and laboratory features than those classified as non-MAS. 
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Selection of candidate clinical and laboratory variables. In univariate analyses, the following 10 variables revealed the greatest ability to 
discriminate patients with MAS from comparison patients: ferritin, platelet count, aspartate transaminase (AST), lactic dehydrogenase (LDH), 
triglycerides, alanine transaminase (ALT), fibrinogen, CNS involvement, hepatomegaly, and hemorrhagic manifestations (Table 2). These variables 
qualified for inclusion in logistic regression analyses aimed to generate candidate classification criteria through the MAS score method. However, 
the ALT was excluded owing to its close correlation with AST and a slightly lower statistical performance. It was replaced by neutrophil count or 
albumin, depending on the model.  
 
Selection of candidate classification criteria. Of the 982 sets of criteria tested, 45 were retained for further evaluation in the consensus 
conference. Of them, 37 (20 generated through the combination of criteria approach and 17 obtained with the MAS score method) were 
represented by criteria which met the statistical requirements listed in the Methods, and 8 were criteria derived from the literature. The statistical 
performance of the 20 best candidate criteria is presented in online supplementary Table T1. The definition and statistics for all 982 criteria tested 
may be provided to the readers upon request to the authors. 
 
Selection of final classification criteria. During the consensus conference, 7 voting sessions were held among the experts until 3 top 
classification criteria were left (criteria no. 466, 472 and 929 in online supplementary Table T1). Notably, the same criteria were selected 
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independently by the two tables confirming convergent validity of the selection process After the last voting session, an 82% consensus was 
reached on the final definition (criteria no. 472 in online supplementary Table T1). A subsequent open discussion led to the decision to include in 
the final definition the presence of fever as a mandatory criterion and the requirement that the patient should have known or suspected sJIA. The 
final classification criteria selected in the consensus conference are presented in Table 3. 
 
Association between final classification criteria and web-based experts’ consensus evaluations. For this multivariable analysis, complete 
data were available on 227 patients. The logistic regression model to evaluate which were the variables included in the final classification criteria 
that most influenced the experts’ decision to classify the patients as having or not having MAS is presented in Table 4. All variables were 
independently correlated with experts’ diagnosis. However, the association was much stronger for ferritin and platelet count. The AUC-ROC of the 
model was 0.99. 
 
Cross-validation of final classification criteria. The evaluation of the ability of the new classification criteria to discriminate MAS from control 
conditions in the entire patient sample (N = 787/1,111), made using the diagnosis of the treating physician as gold standard, showed a sensitivity 
of 0.72, a specificity 0.97, a positive predictive value (PPV) of 93.9%, a negative predictive value (NPV) of 84.8%, an AUC of 0.84, and a kappa value 
for agreement of 0.72 between the diagnosis yielded by the criteria and the diagnosis made by the caring physician. The same analysis made in 
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the patient sample not included in the expert evaluation (n = 415/683) showed a sensitivity of 0.73, a specificity 0.99, a PPV of 97.4%, a NPV of 
85.9%, an AUC of 0.86 and a kappa value of 0.76. 
 
DISCUSSION 
Using a consensus formation and statistical approach, we developed a new set of classification criteria for MAS complicating sJIA (Table 3). 
Because the criteria were established against comparison samples composed of patients with either rheumatologic (active sJIA without evidence 
of MAS) or non-rheumatologic (systemic infection) conditions, they may encounter the interest of a multidisciplinary range of specialists.  
With the exception of fever, the classification criteria do not include clinical manifestations, but are only determined using laboratory 
variables. This choice is in keeping with the common view that the suspicion of MAS is most commonly raised by the detection of subtle 
laboratory alterations, whereas clinical symptoms are often similar to confusable conditions or delayed22. In a previous analysis of the MAS 
sample included in the present study, we found that 4 of the 5 laboratory tests which are part of the criteria (ferritin, platelet count, AST, and 
triglycerides) were among the parameters that showed a percentage change greater than 50% between the last visit before the onset of MAS and 
the onset of MAS. In the same study, ferritin demonstrated the largest change over time, which underscores its major importance in MAS 
detection
10
 and supports its use as a mandatory criterion. The key value of ferritin in the diagnosis of MAS was corroborated by the observation 
that it was the parameter that had the greatest influence on the experts’ classification of patients as MAS or non-MAS (Table 4). 
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Although fever did not discriminate between MAS and control illnesses, as it was recorded in all or nearly all patients in each sample, the 
expert panel considered fever a prerequisite for the presence of MAS. The cardinal diagnostic role of fever is substantiated by the observation 
that it was the highest-ranked clinical feature identified in the Delphi survey
21
. Unfortunately, we lacked reliable information on the pattern of 
fever in the three patient groups. However, it is generally accepted that the onset of MAS is heralded by the shift from the high-spiking 
intermittent pattern typical of active sJIA to a continuous unremitting pattern3,4,23. 
The detection of macrophage hemophagocytosis in bone marrow biopsy specimens or aspirates or reticuloendothelial organ biopsies is 
another frequent and characteristic feature of MAS. However, because hemophagocytosis is often absent at the early stages of MAS10,11 and its 
demonstration requires an invasive procedure, the expert panel deemed it not necessary for the diagnosis of sJIA-associated MAS. Notably, the 
demonstration of hemophagocytosis is not mandatory in both the HLH-2004 and preliminary MAS diagnostic guidelines
15,16
.  
Although possibly useful for diagnostic purposes, the classification criteria are primarily intended for use in clinical trials and research studies. 
Although the criteria revealed high accuracy and face/content validity in consensus and statistical evaluations, it should be taken into account that 
they were developed using the expert consensus as the gold standard. Note that the experts were asked to differentiate MAS from non-MAS 
conditions by examining the clinical features and laboratory values recorded at a single point in time (i.e. at disease onset), and were unaware of 
the patient’s clinical course, laboratory values over time, response to treatment, and outcome. This information was, however, available to the 
treating physician, who made the original diagnosis in the clinical setting. The disparity in the available information may partially explain the high 
proportion (47/161; 29.2%) of patients diagnosed as MAS by the caring physician who were classified as non-MAS by the experts. It is conceivable 
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that because the experts were only provided with the information relevant to the development of the criteria, they tended to confirm the 
diagnosis of MAS only in straightforward and unambiguous cases. Notably, of the 47 patients who had the diagnosis of MAS not confirmed by the 
experts, 30 (63.8%) also did not meet the final classification criteria, 11 (23.4%) were not assessable due to the lack of the laboratory variables 
needed to apply the criteria, and only 6 (12.8%) were classified as MAS by the final classification criteria. In addition, only 18 (46.6%) of the 37 
patients in whom the expert could not agree on the diagnosis were classified as MAS by the final classification criteria.  These findings underscore 
the consistency of experts’ evaluations and support the validity of the final classification criteria. 
That the cutoff values for platelet count and fibrinogen included in the criteria are in the normal range of routine laboratory assessments may 
be regarded as clinically implausible. The same may apply to the cutoffs for aspartate aminotransferase and triglycerides, which are only slightly 
above the upper normal limits. However, it is widely recognized that children with active sJIA often have increased platelet counts (e.g., above 
600-800 x 109/l) as well as elevated fibrinogen levels (e.g., above 500-600 mg/dl) as part of the underlying inflammatory process24,25. Thus,  
paradoxically normal values of platelet count or fibrinogen in the setting of otherwise prominent systemic inflammation may raise the suspicion of 
MAS10,22. Because the levels of serum transaminases and triglycerides are generally normal in children with sJIA who do not have other coexistent 
pathologic conditions (e.g. infectious hepatitis or familial hyperlipidemia), their simple increase above the upper normal limits, combined with the 
other clinical and lab abnormalities, may be sufficient to herald the occurrence of MAS. This fits with the real world patient data used in these 
studies to establish cutoff values that distinguish children with JIA with and without MAS.  
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The analysis of the role of the change in laboratory tests over time in the detection of MAS was a secondary objective of the present project. 
However, this exercise was only made for descriptive purposes, that is, to identify and rank the laboratory tests whose change was felt by the 
experts as most important or useful for the early detection of MAS. Because serial values of lab tests were available for patients with MAS, but not 
for control groups, we could not establish the threshold level of change in each test that had the greatest sensitivity and specificity for the 
diagnosis of MAS. This precluded the possibility to incorporate the change in laboratory values over time in the classification criteria. Due to space 
constraints, this part of the study will be reported in a separate manuscript. 
Recently, several episodes of MAS have been observed in sJIA patients under treatment with the cytokine blockers canakinumab and 
tocilizumab in randomized controlled clinical trials and in post-marketing experience26-28. Because these agents inhibit the biologic effects of IL-1 
and IL-6, respectively, which are among the pro-inflammatory cytokines involved in the physiopathology of MAS
5,29
, it is conceivable that MAS 
episodes developing during treatment with these biologics may lack fever or some of the typical laboratory abnormalities of the syndrome. 
Clinical symptoms of patients with sJIA-associated MAS receiving tocilizumab were found to be milder than those of patients not receiving this 
medication30. Preliminary analyses in patients who had MAS while receiving tocilizumab or canakinumab have shown that a few cases did not 
meet the new criteria did so because of the absence of fever or a peak ferritin level < 684 ng/ml 31,32. However, more data from the real world of 
clinical practice are needed to establish whether the criteria should be refined to increase their power to pick up the instances of MAS occurring 
during treatment with IL-1 and IL-6 inhibitors. 
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Our study should be interpreted in the light of some potential caveats. Patient data were collected through the retrospective review of clinical 
charts. A retrospective analysis is subject to missing and possibly erroneous data. However, because all patient profiles were reviewed by the 
experts and the diagnosis of MAS or non-MAS was confirmed only when a high level of consensus was reached, the impact of this potential 
limitation was likely minimized. Some important diagnostic parameters of MAS, such as sCD25 and sCD163 levels and NK cell activity, could not be 
assessed owing to their unavailability in all patient samples. However, these biomarkers are not routinely assessed, nor are they timely, in most 
pediatric rheumatology centers.  
In summary, we have developed a set of classification criteria for MAS complicating sJIA and provided preliminary evidence of their validity. 
These criteria will help standardize the design and conduct of future therapeutic and research studies and contribute to enhancing the knowledge 
and the awareness of the syndrome. The criteria should undergo a prospective validation process before their widespread use can be 
recommended. 
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Table 1. Comparison of clinical and laboratory features at disease onset between patients classified as MAS or non-MAS by the expert panel. 
  
N 
Patients with MAS 
(n = 95) 
 
N 
Patients with no MAS 
(n = 296) 
 
P 
Clinical manifestations£    
 
 
   Fever 94 93 (98.9) 294 278 (94.6) 0.08 
   Hepatomegaly 94 68 (72.3) 295 75 (25.4) <.0001 
   Splenomegaly 92 53 (57.6) 294 67 (22.8) <.0001 
   Lymphadenopathy 91 48 (52.8) 292 73 (25.0) <.0001 
   Active arthritis 95 63 (66.3) 295 163 (55.3) 0.06 
   Central nervous system involvement 93 40 (43.0) 292 25 (8.6) <.0001 
   Hemorrhagic manifestations 92 25 (27.2) 294 16 (5.4) <.0001 
   Heart involvement 94 27 (28.7) 294 34 (11.6) <.0001 
   Lung involvement 95 27 (28.4) 294 40 (13.6) 0.0009 
   Kidney involvement 95 16 (16.8) 295 16 (5.4) 0.0004 
Laboratory tests§ 
   Hemoglobin, g/dl 95 9.9 (8.0 – 11.2) 289 10.9 (9.4 – 12.2) <.0001 
   White blood cell count, x 10
9
/liter 95 8.1 (3.2 – 12.8) 289 15.3 (9.9 – 20.1) <.0001 
   Neutrophil count, x 109/ liter 82 3.7 (1.5 – 8.0) 236 9.4 (5.1 – 14.2) <.0001 
   Platelet count, x 109/ liter 95 98 (57 – 141) 290 385 (286 – 551) <.0001 
   ESR, mm/hour 90 28 (17 – 65) 245 70 (39 – 93) <.0001 
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   C-reactive protein, mg/dl 85 8.7 (2.4 – 16.1) 282 8.2 (2.4 – 15.6) 0.63 
   Aspartate aminotransferase, units/ liter 93 171 (98 – 436) 284 30 (22 – 45) <.0001 
   Alanine aminotransferase, units/liter 91 115 (43 - 283) 284 18 (12 - 34) <.0001 
   Lactate dehydrogenase, U/liter 81 1,560 (801 – 2,400) 248 482 (362 – 688) <.0001 
   Triglycerides, mg/dl 86 267 (192 – 358) 186 123 (96 – 160) <.0001 
   Albumin, gm/dl 79 3.0 (2.6 – 3.5) 252 3.7 (3.2 – 4.1) <.0001 
   Serum sodium, mEq/liter 80 136 (133 - 140) 259 138 (136 - 141) 0.003 
   Fibrinogen, mg/dl 88 220 (148 – 345) 226 500 (356 – 650) <.0001 
   Ferritin, ng/ml 90 9,094 (2,000 – 19,767) 244 268 (62 – 938) <.0001 
   D-dimer, ng/ml 48 3,579 (1,834 – 7,373) 94 1,638 (528 – 3,325) <.0001 
£Data are the number (percentage). §Values are the median (interquartile range) 
MAS = macrophage activation syndrome; ESR = erythrocyte sedimentation rate 
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Table 2. Univariate analysis of the ability of variables to discriminate patients with MAS from comparison patients (n = 391).  
 n OR 95% CI P 
Clinical features  
     Central nervous system involvement 385 8.1 4.5 – 14.4 <.0001 
     Hepatomegaly 389 7.7 4.5 – 12.9 <.0001 
     Hemorrhagic manifestations 386 6.5 3.3 – 12.8 <.0001 
     Fever 388 5.4 0.7 – 40.9 0.106 
     Splenomegaly  386 4.6 2.8 – 7.6 <.0001 
     Lymphoadenopathy 383 3.4 2.1 – 5.5 <.0001 
     Kidney involvement 390 3.5 1.7 – 7.4 0.0008 
     Heart involvement 388 3.1 1.7 – 5.5 0.0001 
     Lung involvement 389 2.5 1.4 – 4.4 0.0011 
     Active arthritis  390 1.6 1.0 – 2.6 0.0587 
Laboratory features (non-normalized values) 
     Ferritin > 684, ng/ml 334 111.6 26.7 – 465.8 <.0001 
     Platelet count ≤ 181 ,x 109/liter  385 84.3 40 – 177.5 <.0001 
     Aspartate aminotransferase > 48, units/liter  377 51.9 21.7 – 124.4 <.0001 
     Lactate dehydrogenase > 853, U/liter  329 20.0 10.7 – 37.3 <.0001 
     Triglycerides > 156, mg/dl 272 19.6 9.4 – 40.8 <.0001 
     Alanine aminotransferase > 36, units/liter 375 18.0 9.4 – 34.3 <. 0001 
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     Fibrinogen  ≤ 360, mg/dl 314 11.5 6.3 – 21.0 <.0001 
     Neutrophil count ≤ 3.7, x 109/liter 318 5.9 3.4 – 10.5 <.0001 
     D-dimer > 1350, ng/ml 142 5.7 2.4 – 13.4 <.0001 
     ESR ≤ 30, mm/hour 335 5.6 3.3 – 9.5 <.0001 
     Albumin ≤ 3.6, gm/dl 331 5.5 3.0 – 10.1 <.0001 
     Hemoglobin ≤ 8.5, gm/dl 384 4.9 2.7 – 8.8 <.0001 
     White blood cell count ≤ 10.2, x 10
9
/liter 384 4.6 2.8 – 7.5 <.0001 
     Serum sodium ≤ 133, mEq/liter 339 2.9 1.7 – 5.0 0.0002 
     C-reactive protein > 0.86 367 2.4 1.0 – 5.9 0.0501 
Laboratory features (normalized values)  
     Ferritin > 2773.6, ng/ml 334 23.9 12.7 – 44.8 <.0001 
     Aspartate aminotransferase > 44.4, units/liter 377 47.4 21.6 – 103.9 <.0001 
     Alanine aminotransferase > 23, units/liter 375 39.4 14.1 – 110.5 <.0001 
     Lactate dehydrogenase > 238.8, U/liter 329 39.2 18.2 – 84.6 <.0001 
     Triglycerides > 193.9, mg/dl 272 16.3 8.7 – 30.8 <.0001 
     Fibrinogen ≤ 318.9, mg/dl 314 11.0 6.1 – 20.0 <.0001 
    Albumin ≤ 3.9, gm/dl 331 6.4 3.6 – 11.3 <.0001 
    D-dimer > 1320.3, ng/ml 142 5.2 2.1 – 12.7 <.0001 
     Serum sodium ≤ 135, mEq/liter 339 3.3 1.9 – 5.6 <.0001 
OR = odds ratio; 95% CI = 95% confidence interval. 
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Table 3. The classification criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 
A febrile patient with known or suspected systemic juvenile idiopathic arthritis is classified as 
having macrophage activation syndrome if the following criteria are met: 
Ferritin > 684 ng/ml 
and 
any 2 of the following: 
Platelet count ≤ 181 x109/liter 
Aspartate aminotransferase > 48 U/liter 
Triglycerides > 156 mg/dl 
Fibrinogen ≤ 360 mg/dl 
Laboratory abnormalities should not be otherwise explained by the patient’s condition, such as concomitant immune-mediated 
thrombocytopenia, infectious hepatitis, visceral leishmaniasis, or familial hyperlipidemia.   
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Table 4. Logistic regression model to assess the association of the variables included in the final classification criteria and the web-based experts’ 
consensus of patients’ classification as MAS or non-MAS* 
 
Explanatory variable OR 95% CI P
§
 
Ferritin > 684 ng/ml >999.999 40.6 - >999.999 <.0001 
Platelet count ≤ 181 x10⁹/l 237.0 18.2 - >999.999 <.0001 
Triglycerides > 156 mg/dl 18.3 2.0 – 163.9 0.009 
Fibrinogen ≤ 360 mg/dl 16.0 2.0 – 126.4 0.009 
Aspartate aminotransferase > 48 U/l 10.0 1.3 – 78.4 0.029 
*The web-based experts’ consensus on patients’ classification as MAS or non-MAS was the dependent variable. Complete data were available on 
227 patients. The area under the receiver operating characteristic curve of the model was 0.99. OR = odds ratio; 95% CI = 95% confidence interval. 
§By likelihood ratio test 
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LEGEND TO FIGURE 
 
Figure 1. Patient samples evaluated in the study and results of web-based expert evaluations 
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Online supplementary Table T1. Composition and statistical performance of the top 20 classification criteria  
N Classification criteria Derivation Sensitivity Specificit
y 
PPV NPV AUC kappa
929 Ferritin >684 ng/ml (84); PLT ≤ 181 x109/liter (13); AST > 48 U/l (1); 
Triglycerides >156 mg/dl (1); Fibrinogen < 360 mg/dl (1) - Total score 
> 86 
MS 0.95 1.0 100 97.4 0.97 0.96
932 Ferritin >684 ng/ml (84); PLT ≤ 181 x109/ liter (13.5); Triglycerides 
>156 mg/dl (1.5); Fibrinogen < 360 mg/dl (1) - Total score > 85.5 
MS 0.95 0.99 98.7 97.4 0.97 0.95
943 Ferritin >684 ng/ml (70); PLT ≤ 181 x109/ liter (25); Triglycerides 
>156 mg/dl (2); Fibrinogen < 360 mg/dl (3) - Total score > 73 
MS 0.95 0.99 98.7 97.4 0.97 0.95
941 Ferritin >684 ng/ml (68); PLT ≤ 181 x109/ liter (25); Triglycerides 
>156 mg/dl (1); Fibrinogen < 360 mg/dl (3); Albumin ≤ 3.6 g/dl (3) - 
Total score > 72 
MS 0.95 0.99 96.9 97.9 0.97 0.94
976 Ferritin >684 ng/ml (59); PLT ≤ 181 x109/ liter (39); Fibrinogen < 360 
mg/dl (1); Hepatomegaly (1) - Total score > 60 
MS 0.95 0.99 96.4 98.1 0.97 0.94
930 Ferritin >684 ng/ml (84.5); PLT ≤ 181 x109/ liter (13); AST > 48 U/l 
(1); Triglycerides >156 mg/dl (1.5) - Total score > 86 
MS 0.96 0.97 93.9 98.1 0.97 0.93
931 Ferritin >684 ng/ml (84.5); PLT ≤ 181 x109/ liter (13.5); AST > 48 U/l 
(1); Fibrinogen < 360 mg/dl (1) - Total score > 85.5 
MS 0.95 0.98 95.2 98.1 0.97 0.93
942 Ferritin >684 ng/ml (68); PLT ≤ 181 x109/ liter (25); Fibrinogen < 360 
mg/dl (3); Albumin ≤ 3.6 g/dl (3) - Total score > 72 
MS 0.93 0.99 97.1 97.4 0.96 0.93
529 At least 4 of the following: Ferritin > 2774 ng/ml; PLT < 181 x109/ liter; CC 0.93 0.98 95.4 97.7 0.96 0.92
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AST > 44.4 U/l; Triglycerides > 194 mg/dl; Fibrinogen < 319 mg/dl; 
Hepatomegaly 
798 Ferritin ≥ 500 ng/ml + any 2 of the following: PLT ≤ 262 x109/ liter; 
AST > 59 U/l; WBC ≤ 4 x109/l; Fibrinogen ≤ 250 mg/dl 
CC 0.94 0.98 94.4 97.9 0.96 0.92
934 Ferritin >684 ng/ml (85.5); PLT ≤ 181 x109/ liter (13.5); Fibrinogen < 
360 mg/dl (1) - Total score > 85.5 
MS 0.95 0.97 92.1 98.0 0.96 0.91
935 Ferritin >684 ng/ml (85); PLT ≤ 181 x109/ liter (13.5); Triglycerides 
>156 mg/dl (1.5) - Total score > 86.5 
MS 0.88 1.0 100 94.2 0.94 0.91
946 Ferritin >684 ng/ml (71); PLT ≤ 181 x109/ liter (26); Fibrinogen < 360 
mg/dl (3) - Total score > 71 
MS 0.95 0.97 92.1 98.0 0.96 0.91
947 Ferritin >684 ng/ml (72); PLT ≤ 181 x109/ liter (26); Triglycerides 
>156 mg/dl (2) - Total score > 74 
MS 0.88 1.0 100 94.2 0.94 0.91
977 Ferritin >684 ng/ml (60); PLT ≤ 181 x109/ liter (39); Fibrinogen < 360 
mg/dl (1) - Total score > 60 
MS 0.95 0.97 92.1 98.0 0.96 0.91
307 Ferritin > 684 ng/ml and PLT ≤ 181 x109/ liter CC 0.86 1.0 100 94.9 0.93 0.90
466 Ferritin > 684 ng/ml and PLT ≤ 181 x109/ liter + any 1 of the following: 
AST > 48 U/l; Triglycerides > 156 mg/dl; Fibrinogen < 360 mg/dl 
CC 1.0 0.95 85.6 100 0.97 0.90
472 Ferritin > 684 ng/ml + any 2 of the following: PLT ≤ 181 x109/ liter; 
AST > 48 U/l; Triglycerides > 156 mg/dl; Fibrinogen ≤ 360 mg/dl 
CC 0.97 0.96 89.7 98.7 0.96 0.90
481 Any 3 of the following: Ferritin > 2774 ng/ml; PLT < 181 x109/ liter; 
AST > 44.4 U/l; Triglycerides > 194 mg/dl; Fibrinogen < 319 mg/dl) 
COC 0.96 0.96 89.2 98.6 0.96 0.90
580 Ferritin > 684 ng/ml and PLT < 181 x109/ liter + any 1 of the following: CC 0.86 1.0 100 94.9 0.93 0.90
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AST > 48 U/l; Triglycerides > 156 mg/dl; Fibrinogen < 360 mg/dl; 
Hepatomegaly 
PLT = platelet count; AST = aspartate aminotransferase; MS = criteria derived from the MAS score method (see text for 
explanation); CC = criteria derived through the combination of criteria approach (see text for explanation); PPV = positive 
predictive value; NPV = negative predictive value; AUC: area under the curve. The number in parenthesis for the items 
included in the criteria derived through the MS method are the weights yielded by multivariable logistic regression analyses. 
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